AVB 620

Drug Profile

AVB 620

Alternative Names: Activated cell penetrating peptide - Avelas Biosciences; Fluorescent probe - Avelas Biosciences; Fluorescent protease-activated peptide - Avelas Biosciences

Latest Information Update: 17 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avelas BioSciences
  • Class Diagnostic agents; Diagnostic conjugates; Imaging agents; Peptide diagnostics
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 05 Jul 2017 Phase-II clinical trials in Breast cancer (Diagnosis, Late-stage disease) in USA (IV) (NCT03113825)
  • 08 Dec 2016 Avelas Biosciences completes a phase Ib trial in Breast cancer (Diagnosis) in USA (NCT02391194)
  • 08 Dec 2016 Avelas Biosciences plans a phase II trial for Breast cancer (Late-stage disease, Diagnosis) (IV) (NCT03113825)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top